Piroxicam and Levonorgestrel Co-treatment for Emergency Contraception (NCT03614494) | Clinical Trial Compass
CompletedPhase 2/3
Piroxicam and Levonorgestrel Co-treatment for Emergency Contraception
Hong Kong860 participantsStarted 2018-08-20
Plain-language summary
This is a randomised controlled trial aimed at comparing the efficacy of levonorgestrel (LNG) co-administered with piroxicam or placebo for oral emergency contraception (EC). Piroxicam is a non-steroidal anti-inflammatory drug (NSAID) commonly used as a pain-killer in inflammatory conditions. Efficacy will be measured as the percentage of pregnancies prevented.
Who can participate
Age range18 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* healthy women aged 18 years or above;
* requesting emergency contraception within 72 h of a single act of unprotected intercourse in the current menstrual cycle;
* having menstrual cycles between 24 and 42 days
* willing to abstain from further acts of unprotected intercourse and;
* available for follow-up over the next 6 weeks.
Exclusion Criteria:
* post-abortion or postpartum and period have not yet returned,
* being on prescription drugs currently
* having unprotected intercourse in this cycle more than 72 hours or more than once before attending the clinic,
* being found pregnant at the time of presentation,
* breastfeeding,
* having been sterilized (or partner having been sterilized) or having intrauterine contraceptive device in-situ,
* uncertain about the date of the last menstrual period,
* having used hormonal contraceptive (including EC pill) or NSAID in the current or past one cycle,
* having history of asthma, urticarial or other allergic reactions to piroxicam, aspirin or other NSAIDs,
* having history of ischaemic heart disease in the past one year
* having history of pelvic ulcer disease and/or gastrointestinal bleeding